301
Views
24
CrossRef citations to date
0
Altmetric
Review

Interindividual variability in oral antidiabetic drug disposition and response: the role of drug transporter polymorphisms

, PharmD MPH, , MPH & , PharmD
Pages 529-544 | Published online: 18 May 2008

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (5)

Andreas Holstein, Winfried Beil & Peter Kovacs. (2012) CYP2C metabolism of oral antidiabetic drugs - impact on pharmacokinetics, drug interactions and pharmacogenetic aspects. Expert Opinion on Drug Metabolism & Toxicology 8:12, pages 1549-1563.
Read now
André J Scheen. (2010) Pharmacokinetic and pharmacodynamic evaluation of sitagliptin plus metformin. Expert Opinion on Drug Metabolism & Toxicology 6:10, pages 1265-1276.
Read now
Christina L Aquilante. (2010) Sulfonylurea pharmacogenomics in Type 2 diabetes: the influence of drug target and diabetes risk polymorphisms. Expert Review of Cardiovascular Therapy 8:3, pages 359-372.
Read now
Andreas Holstein & Winfried Beil. (2009) Oral antidiabetic drug metabolism: pharmacogenomics and drug interactions. Expert Opinion on Drug Metabolism & Toxicology 5:3, pages 225-241.
Read now

Articles from other publishers (19)

Lucy Darakjian, Malavika Deodhar, Jacques Turgeon & Veronique Michaud. (2021) Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity. International Journal of Molecular Sciences 22:9, pages 4967.
Crossref
Min Joon Lee, Viranda H. Jayalath, Wei Xu, Lin Lu, Stephen J. Freedland, Neil E. Fleshner, Girish S. Kulkarni, Antonio Finelli, Theodorus H. van der Kwast & Robert J. Hamilton. (2020) Association between metformin medication, genetic variation and prostate cancer risk. Prostate Cancer and Prostatic Diseases 24:1, pages 96-105.
Crossref
Sophie Gravel, Jean‐Louis Chiasson, Fleur Gaudette, Jacques Turgeon & Veronique Michaud. (2019) Use of 4β‐Hydroxycholesterol Plasma Concentrations as an Endogenous Biomarker of CYP3A Activity: Clinical Validation in Individuals With Type 2 Diabetes. Clinical Pharmacology & Therapeutics 106:4, pages 831-840.
Crossref
Sophie Gravel, Benoit Panzini, Francois Belanger, Jacques Turgeon & Veronique Michaud. (2019) A Pilot Study towards the Impact of Type 2 Diabetes on the Expression and Activities of Drug Metabolizing Enzymes and Transporters in Human Duodenum. International Journal of Molecular Sciences 20:13, pages 3257.
Crossref
Y. W. Francis Lam, Ravindranath Duggirala, Christopher P. Jenkinson & Rector Arya. 2019. Pharmacogenomics. Pharmacogenomics 247 269 .
Sophie Gravel, Jean-Louis Chiasson, Suzanne Dallaire, Jacques Turgeon & Veronique Michaud. (2018) Evaluating the impact of type 2 diabetes mellitus on CYP450 metabolic activities: protocol for a case–control pharmacokinetic study. BMJ Open 8:2, pages e020922.
Crossref
Sarah Maximos, Michel Chamoun, Sophie Gravel, Jacques Turgeon & Veronique Michaud. (2017) Tissue Specific Modulation of cyp2c and cyp3a mRNA Levels and Activities by Diet-Induced Obesity in Mice: The Impact of Type 2 Diabetes on Drug Metabolizing Enzymes in Liver and Extra-Hepatic Tissues. Pharmaceutics 9:4, pages 40.
Crossref
Puneet Gaitonde, Parag Garhyan, Catharina Link, Jenny Y. Chien, Mirjam N. Trame & Stephan Schmidt. (2016) A Comprehensive Review of Novel Drug?Disease Models in Diabetes Drug Development. Clinical Pharmacokinetics 55:7, pages 769-788.
Crossref
Henk den Ouden, Linette Pellis, Guy E. H. M. Rutten, Ilse K. Geerars-van Vonderen, Carina M. Rubingh, Ben van Ommen, Marjan J. van Erk & Joline W. J. Beulens. (2016) Metabolomic biomarkers for personalised glucose lowering drugs treatment in type 2 diabetes. Metabolomics 12:2.
Crossref
Peter Kovacs & Ewan Pearson. 2016. The Genetics of Type 2 Diabetes and Related Traits. The Genetics of Type 2 Diabetes and Related Traits 483 497 .
Abdolkarim Mahrooz, Hassan Parsanasab, Mohammad Bagher Hashemi-Soteh, Zahra Kashi, Adele Bahar, Ahad Alizadeh & Maliheh Mozayeni. (2014) The role of clinical response to metformin in patients newly diagnosed with type 2 diabetes: a monotherapy study. Clinical and Experimental Medicine 15:2, pages 159-165.
Crossref
A. Emami‐Riedmaier, E. Schaeffeler, A. T. Nies, K. Mörike & M. Schwab. (2015) Stratified medicine for the use of antidiabetic medication in treatment of type II diabetes and cancer: where do we go from here? . Journal of Internal Medicine 277:2, pages 235-247.
Crossref
Tao Wang, Yan Wang, Dong-Mei Lv, Jin-Fang Song, Qian Lu, Xing Gao, Fan Zhang, Hao Guo, Wei Li & Xiao-Xing Yin. (2014) Effects of NOS1AP rs12742393 Polymorphism on Repaglinide Response in Chinese Patients with Type 2 Diabetes Mellitus . Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 34:2, pages 131-139.
Crossref
Douglas B. Kell. (2013) Finding novel pharmaceuticals in the systems biology era using multiple effective drug targets, phenotypic screening and knowledge of transporters: where drug discovery went wrong and how to fix it. FEBS Journal 280:23, pages 5957-5980.
Crossref
Christina L. Aquilante & Y.W. Francis Lam. 2013. Pharmacogenomics. Pharmacogenomics 247 271 .
Gaia Chiara Mannino & Giorgio Sesti. (2012) Individualized Therapy for Type 2 Diabetes. Molecular Diagnosis & Therapy 16:5, pages 285-302.
Crossref
Luka Peternel, Katja Kristan, Marija Petruševska, Tea Lanišnik Rižner & Igor Legen. (2012) Suitability of Isolated Rat Jejunum Model for Demonstration of Complete Absorption in Humans for BCS-Based Biowaiver Request. Journal of Pharmaceutical Sciences 101:4, pages 1436-1449.
Crossref
Vangelis G Manolopoulos, Georgia Ragia & Anna Tavridou. (2011) Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics 12:8, pages 1161-1191.
Crossref
Andreas HolsteinAngela Seeringer & Peter Kovacs. (2011) Therapy with oral antidiabetic drugs: applied pharmacogenetics. The British Journal of Diabetes & Vascular Disease 11:1, pages 10-16.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.